Is TG Therapeutics Inc common stock (TGTX) a Stock to Watch After Gaining 42.63% This Week?

TG Therapeutics Inc common stock (TGTX) stock has gained 42.63% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

TG Therapeutics Inc common stock has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TGTX!

See Full TGTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With TGTX Stock Today?

TG Therapeutics Inc common stock (TGTX) stock is down -4.7% while the S&P 500 is higher by 0.15% as of 11:26 AM on Monday, Nov 6. TGTX has fallen -$0.52 from the previous closing price of $11.06 on volume of 1,780,763 shares. Over the past year the S&P 500 has gained 14.67% while TGTX is higher by 86.22%. TGTX lost -$0.27 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for TG Therapeutics Inc common stock click here.

More About TG Therapeutics Inc common stock

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Click Here to get the full Stock Report for TG Therapeutics Inc common stock stock.